[go: up one dir, main page]

TW200744585A - Inhibitors of PAI-1 for treatment of muscular conditions - Google Patents

Inhibitors of PAI-1 for treatment of muscular conditions

Info

Publication number
TW200744585A
TW200744585A TW096106440A TW96106440A TW200744585A TW 200744585 A TW200744585 A TW 200744585A TW 096106440 A TW096106440 A TW 096106440A TW 96106440 A TW96106440 A TW 96106440A TW 200744585 A TW200744585 A TW 200744585A
Authority
TW
Taiwan
Prior art keywords
muscle
inhibitors
pai
treatment
muscular conditions
Prior art date
Application number
TW096106440A
Other languages
English (en)
Inventor
David Leroy Crandall
George Phillip Vlasuk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200744585A publication Critical patent/TW200744585A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW096106440A 2006-02-27 2007-02-26 Inhibitors of PAI-1 for treatment of muscular conditions TW200744585A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77752106P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
TW200744585A true TW200744585A (en) 2007-12-16

Family

ID=38438022

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096106440A TW200744585A (en) 2006-02-27 2007-02-26 Inhibitors of PAI-1 for treatment of muscular conditions

Country Status (20)

Country Link
US (1) US20070203220A1 (zh)
EP (1) EP2010171A2 (zh)
JP (1) JP2009528290A (zh)
KR (1) KR20080108407A (zh)
CN (1) CN101384256A (zh)
AR (1) AR059629A1 (zh)
AU (1) AU2007217363A1 (zh)
BR (1) BRPI0710964A2 (zh)
CA (1) CA2643731A1 (zh)
CR (1) CR10253A (zh)
EC (1) ECSP088699A (zh)
GT (1) GT200800167A (zh)
IL (1) IL192975A0 (zh)
MX (1) MX2008011015A (zh)
NO (1) NO20083438L (zh)
PE (1) PE20071017A1 (zh)
RU (1) RU2008128475A (zh)
TW (1) TW200744585A (zh)
WO (1) WO2007098278A2 (zh)
ZA (1) ZA200807357B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850324A (zh) * 2006-08-07 2013-01-02 硬木药品公司 吲哚化合物
GB0812192D0 (en) * 2008-07-03 2008-08-13 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN103724357B (zh) * 2012-10-11 2016-06-08 中国药科大学 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
JP6872195B2 (ja) * 2015-10-29 2021-05-19 国立大学法人東北大学 コラーゲン産生抑制剤
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
CA3182911A1 (en) * 2020-05-11 2021-11-18 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2006510673A (ja) * 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体
DE60306547T2 (de) * 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
DE60327550D1 (de) * 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60306548T2 (de) * 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
JP2008510815A (ja) * 2004-08-23 2008-04-10 ワイス 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）としてのオキサゾロ−ナフチル酸
AU2005277137A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
CA2577846A1 (en) * 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
CN101263115A (zh) * 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途

Also Published As

Publication number Publication date
CA2643731A1 (en) 2007-08-30
ZA200807357B (en) 2009-08-26
KR20080108407A (ko) 2008-12-15
JP2009528290A (ja) 2009-08-06
AU2007217363A1 (en) 2007-08-30
CN101384256A (zh) 2009-03-11
ECSP088699A (es) 2008-09-29
WO2007098278A3 (en) 2008-03-20
EP2010171A2 (en) 2009-01-07
PE20071017A1 (es) 2007-11-12
NO20083438L (no) 2008-10-31
CR10253A (es) 2008-11-18
MX2008011015A (es) 2008-11-14
RU2008128475A (ru) 2010-04-10
IL192975A0 (en) 2009-08-03
BRPI0710964A2 (pt) 2012-02-28
WO2007098278A2 (en) 2007-08-30
US20070203220A1 (en) 2007-08-30
AR059629A1 (es) 2008-04-16
GT200800167A (es) 2009-01-15

Similar Documents

Publication Publication Date Title
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2007092622A3 (en) Compositions and methods for treating bone
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2011064154A3 (en) Composition for metal electroplating comprising leveling agent
MX340064B (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
MX2012004780A (es) Inhibidores de akt.
TW200744585A (en) Inhibitors of PAI-1 for treatment of muscular conditions
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
IN2012DN02624A (zh)
WO2010021934A3 (en) Azaindole inhibitors of iap
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
TW200806297A (en) Methods for treating cognitive and other disorders
MX2010007543A (es) Inhibidores de iap.
TW200716088A (en) Formulations and methods for treating amyloidosis
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала